{"protocolSection": {"identificationModule": {"nctId": "NCT03714815", "orgStudyIdInfo": {"id": "AC-055G203"}, "secondaryIdInfos": [{"id": "2018-001603-37", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Actelion", "class": "INDUSTRY"}, "briefTitle": "A Long Term Study to Find Out if Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease", "officialTitle": "A Long-term, Multicenter, Single-arm, Open-label Extension of the SERENADE Study, to Assess the Safety and Efficacy of Macitentan in Subjects With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease", "acronym": "SERENADE OL"}, "statusModule": {"statusVerifiedDate": "2023-09", "overallStatus": "TERMINATED", "whyStopped": "the absence of a positive trend in all efficacy parameters indicates that macitentan 10 mg does not have a beneficial effect in patients with HFpEF and PVD.", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2018-12-07", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2021-10-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2021-10-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2018-10-19", "studyFirstSubmitQcDate": "2018-10-19", "studyFirstPostDateStruct": {"date": "2018-10-22", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2022-10-12", "resultsFirstSubmitQcDate": "2022-10-12", "resultsFirstPostDateStruct": {"date": "2022-11-04", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-09-13", "lastUpdatePostDateStruct": {"date": "2023-09-22", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Actelion", "class": "INDUSTRY"}, "collaborators": [{"name": "Almac Clinical Technologies, LLC", "class": "UNKNOWN"}, {"name": "Frontier Science & Technology Research Foundation, Inc.", "class": "INDUSTRY"}, {"name": "Covance Central Laboratory Services, LP", "class": "UNKNOWN"}, {"name": "Chiltern International Ltd.", "class": "INDUSTRY"}, {"name": "WorldCare Clinical, LLC", "class": "UNKNOWN"}, {"name": "AcitGraph", "class": "OTHER"}, {"name": "Medidata Solutions", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The aim of this open-label (OL) extension trial is to study the long-term safety and efficacy of macitentan in subjects with heart failure with preserved ejection fraction (HFpEF) and pulmonary vascular disease (PVD) beyond the treatment in the double-blind parent SERENADE study (AC-055G202, NCT03153111). Furthermore, this OL extension study will give eligible subjects of the main study (SERENADE/AC-055G202, NCT03153111) an opportunity to continue or start receiving macitentan."}, "conditionsModule": {"conditions": ["Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease"], "keywords": ["pulmonary vascular disease", "macitentan", "heart failure with preserved ejection fraction"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "interventionModelDescription": "Subjects who remained in main study (SERENADE/AC-055G202, NCT03153111) after randomization and who meet the eligibility criteria described will be eligible to enter this single-arm OL extension study. All enrolled subjects will receive macitentan 10 mg. For this OL extension study no primary efficacy endpoint has been defined and all efficacy endpoints are of exploratory nature. The ones listed below are considered safety endpoints.", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 91, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Open-label treatment period", "type": "EXPERIMENTAL", "description": "oral administration of 10 mg macitentan once daily", "interventionNames": ["Drug: macitentan 10 mg"]}], "interventions": [{"type": "DRUG", "name": "macitentan 10 mg", "description": "macitentan 10 mg, film-coated tablet, oral use", "armGroupLabels": ["Open-label treatment period"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Participants With All-cause Deaths up to 30 Days After Study Treatment Discontinuation", "description": "Number of participants with all-cause deaths up to 30 days after study treatment discontinuation were reported. All-cause deaths are defined as all anticipated and unanticipated deaths due to any cause.", "timeFrame": "Up to 30 days after study treatment discontinuation (treatment exposure ranged from 0.4 to 126 weeks)"}, {"measure": "Number of Participants With All-cause Hospital Admissions up to 30 Days After Study Treatment Discontinuation", "description": "Number of participants with all-cause hospital admissions up to 30 days after study treatment discontinuation were reported.", "timeFrame": "Up to 30 days after study treatment discontinuation (treatment exposure ranged from 0.4 to 126 weeks)"}, {"measure": "Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) up to 30 Days After Study Treatment Discontinuation", "description": "An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is a suspected transmission of any infectious agent via a medicinal product, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above. Any AE and SAE occurring at or after the study treatment start up to 30 days after end of treatment (EOT) within the analysis set was considered to be treatment-emergent.", "timeFrame": "Up to 30 days after study treatment discontinuation (treatment exposure ranged from 0.4 to 126 weeks)"}, {"measure": "Number of Participants With TEAEs Leading to Premature Discontinuation of Study Treatment", "description": "An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. Any AE occurring at or after the study treatment start up to 30 days after EOT within the analysis set was considered to be treatment-emergent.", "timeFrame": "Up to 30 days after study treatment discontinuation (treatment exposure ranged from 0.4 to 126 weeks)"}, {"measure": "Change From Baseline in Systolic and Diastolic Arterial Blood Pressure (BP) at Week 24", "description": "Change from baseline in systolic and diastolic arterial BP at Week 24 was reported.", "timeFrame": "Baseline and Week 24"}, {"measure": "Change From Baseline in Systolic and Diastolic Arterial Blood Pressure (BP) at Week 52", "description": "Change from baseline in systolic and diastolic arterial BP at Week 52 was reported.", "timeFrame": "Baseline and Week 52"}, {"measure": "Change From Baseline in Pulse Rate at Week 24", "description": "Change from baseline in pulse rate at Week 24 was reported.", "timeFrame": "Baseline and Week 24"}, {"measure": "Change From Baseline in Pulse Rate at Week 52", "description": "Change from baseline in pulse rate at Week 52 was reported.", "timeFrame": "Baseline and Week 52"}, {"measure": "Change From Baseline in Body Weight at Week 24", "description": "Change from baseline in body weight at Week 24 was reported.", "timeFrame": "Baseline and Week 24"}, {"measure": "Change From Baseline in Body Weight at Week 52", "description": "Change from baseline in body weight at Week 52 was reported.", "timeFrame": "Baseline and Week 52"}, {"measure": "Number of Participants With Treatment-emergent Marked Laboratory Abnormalities (MLAs) up to 30 Days After Study Treatment Discontinuation", "description": "Number of participants with treatment-emergent MLAs (Hemoglobin \\[grams/Liter{L}\\], Hematocrit \\[L/L\\], Leukocytes \\[10\\^9cells/L\\], Lymphocytes \\[10\\^9cells/L\\], Alanine Aminotransferase \\[Units/L {U/L}\\], Aspartate Aminotransferase \\[U/L\\], Bilirubin \\[micromoles/L {mcmol/L}\\], Alkaline Phosphatase \\[U/L\\], Creatinine \\[mcmol/L\\], Urea Nitrogen \\[mmol/L\\], Urate \\[mcmol/L\\], Potassium \\[mmol/L\\], Sodium \\[mmol/L\\], Magnesium \\[mmol/L\\], Calcium \\[mmol/L\\] were reported. Abnormalities that occurred after study treatment start and up to 30 days after study treatment discontinuation, that were not present at baseline, were treatment-emergent. Here, \\> signifies greater than; \\< signifies less than; ULN signifies upper limit of normal; and L=Low, H=High, LL=low/low, HH=high/high, LLL=lower/worse than LL, HHH=higher/worse than HH.", "timeFrame": "Up to 30 days after study treatment discontinuation (treatment exposure ranged from 0.4 to 126 weeks)"}, {"measure": "Change From Baseline in Hemoglobin at Week 24", "description": "Change from baseline in hemoglobin at Week 24 was reported.", "timeFrame": "Baseline and Week 24"}, {"measure": "Change From Baseline in Hemoglobin at Week 52", "description": "Change from baseline in hemoglobin at Week 52 was reported.", "timeFrame": "Baseline and Week 52"}, {"measure": "Change From Baseline in Leukocytes and Platelets at Week 24", "description": "Change from baseline in leukocytes and platelets at Week 24 was reported.", "timeFrame": "Baseline and Week 24"}, {"measure": "Change From Baseline in Leukocytes and Platelets at Week 52", "description": "Change from baseline in leukocytes and platelets at Week 52 was reported.", "timeFrame": "Baseline and Week 52"}, {"measure": "Change From Baseline in Alanine Aminotransferase and Aspartate Aminotransferase at Week 24", "description": "Change from baseline in alanine aminotransferase and aspartate aminotransferase at Week 24 was reported.", "timeFrame": "Baseline and Week 24"}, {"measure": "Change From Baseline in Alanine Aminotransferase and Aspartate Aminotransferase at Week 52", "description": "Change from baseline in alanine aminotransferase and aspartate aminotransferase at Week 52 was reported.", "timeFrame": "Baseline and Week 52"}, {"measure": "Change From Baseline in Bilirubin at Week 24", "description": "Change from baseline in bilirubin at Week 24 was reported.", "timeFrame": "Baseline and Week 24"}, {"measure": "Change From Baseline in Bilirubin at Week 52", "description": "Change from baseline in bilirubin at Week 52 was reported.", "timeFrame": "Baseline and Week 52"}, {"measure": "Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 24", "description": "Change from baseline in eGFR rate at Week 24 was reported.", "timeFrame": "Baseline and Week 24"}, {"measure": "Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 52", "description": "Change from baseline in eGFR rate at Week 52 was reported.", "timeFrame": "Baseline and Week 52"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Signed and dated Informed Consent Form (ICF).\n* Participant remained in the main study (SERENADE/AC-055G202, NCT03153111) for: a) 52 weeks after randomization if entered this Open-label (OL) extension study prior to protocol Version 4, b) At least 24 weeks after randomization if entering this OL extension study under protocol Version 4\n* A woman of childbearing potential is eligible only if: (1) Negative pre-treatment serum pregnancy test; (2) Agreement to undertake monthly pregnancy tests from the enrollment visit up to at least 30 days after study treatment discontinuation; and (2) Agreement to use reliable contraception from at least 30 days prior to the enrollment visit up to at least 30 days after study treatment discontinuation.\n\nExclusion Criteria:\n\n* Premature discontinuation of study treatment in the main study (SERENADE/AC-055G202, NCT03153111) due to an adverse event related to: (1) Edema or fluid retention; (2) Worsening of heart failure; (3) Liver aminotransferase elevation; and (4) Study treatment, based on investigators' discretion\n* Liver aminotransferase elevations, at the enrollment visit, fulfilling the following criteria: (1) Alanine amino transferase (ALT) / aspartate aminotransferase (AST) greater than or equal to (\\>=) 8 \\* the upper limit of normal (ULN); (2) ALT/AST \\>= 3 \\* ULN and associated clinical symptoms of liver injury, for example: nausea, vomiting, fever, abdominal pain, jaundice, unusual lethargy or fatigue, flu-like syndrome (arthralgia, myalgia, fever); and (3) ALT/AST \\>= 3 \\* ULN and associated increase in total bilirubin to \\>= 2 \\* ULN\n* Treatment with the following forbidden medications within 1 month prior to the enrollment visit: (1) Treatments that may interfere with the assessment of efficacy (that is, endothelin receptor antagonists, prostanoids, phosphodiesterase-5 inhibitors, guanylate cyclase stimulators); (2) Strong cytochrome P-450 3A4 (CYP3A4) inducers such as rifabutin, rifampin, rifampicin, rifapentin, carbamazepine, phenobarbital, phenytoin, or St. John's wort; (3) Strong CYP3A4 inhibitors such as ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, nefazodone, ritonavir, and saquinavir or a moderate dual CYP3A4/CYP2C9 inhibitor (for example, fluconazole or amiodarone) or co-administration of a combination of moderate CYP3A4 (for example, ciprofloxacin, cyclosporine, diltiazem, erythromycin, verapamil) and moderate CYP2C9 inhibitors (for example, miconazole, piperine), in the 1-month period prior to baseline. This will not necessarily apply to participants who are already well-managed on such an ongoing combination; and (4) any other investigational treatment\n* Pregnant, planning to be become pregnant or lactating.\n* Any known factor or disease that might interfere with treatment compliance, study conduct, or interpretation of the results, such as drug or alcohol dependence or psychiatric disease.\n* Known hypersensitivity to macitentan or drugs of the same class, or any of the study drug excipients (for example, soy lecithin, lactose)", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "William Byra, MD", "affiliation": "Actelion", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "South Denver Cardiology Associates PC", "city": "Littleton", "state": "Colorado", "zip": "80120", "country": "United States", "geoPoint": {"lat": 39.61332, "lon": -105.01665}}, {"facility": "Northwestern University Feinberg School of Medicine", "city": "Chicago", "state": "Illinois", "zip": "60611", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "University Of Iowa - Hospitals & Clinics", "city": "Iowa City", "state": "Iowa", "zip": "52242-1081", "country": "United States", "geoPoint": {"lat": 41.66113, "lon": -91.53017}}, {"facility": "University of Maryland", "city": "Baltimore", "state": "Maryland", "zip": "21201", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "Massachusetts General Hospital", "city": "Boston", "state": "Massachusetts", "zip": "02114", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}, {"facility": "Washington University School of Medicine", "city": "Saint Louis", "state": "Missouri", "zip": "63110", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Allegheny", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15212", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "North Dallas Research Associates", "city": "McKinney", "state": "Texas", "zip": "75069", "country": "United States", "geoPoint": {"lat": 33.19762, "lon": -96.61527}}, {"facility": "Inova Heart and Vascular Institute", "city": "Falls Church", "state": "Virginia", "zip": "22042", "country": "United States", "geoPoint": {"lat": 38.88233, "lon": -77.17109}}, {"facility": "MultiCare Health System", "city": "Tacoma", "state": "Washington", "zip": "98405", "country": "United States", "geoPoint": {"lat": 47.25288, "lon": -122.44429}}, {"facility": "Aurora Saint Lukes Medical Center", "city": "Milwaukee", "state": "Wisconsin", "zip": "53215", "country": "United States", "geoPoint": {"lat": 43.0389, "lon": -87.90647}}, {"facility": "Instituto de Investigaciones Clinicas Mar del Plata", "city": "Mar Del Plata, Buenos Aires", "zip": "B7600FZN", "country": "Argentina"}, {"facility": "Medizinische Universit\u00e4t Wien", "city": "Vienna", "zip": "1090", "country": "Austria", "geoPoint": {"lat": 48.20849, "lon": 16.37208}}, {"facility": "Maestri E Kormann Consultoria M\u00e9dico- Cient\u00edfica Ltda", "city": "Blumenau", "zip": "89020-430", "country": "Brazil", "geoPoint": {"lat": -26.91944, "lon": -49.06611}}, {"facility": "Instituto do Coracao de Mar\u00edlia", "city": "Marilia", "zip": "17515-000", "country": "Brazil", "geoPoint": {"lat": -22.21389, "lon": -49.94583}}, {"facility": "Diagnostic - Consulting Center I-Sliven", "city": "Sliven", "zip": "8800", "country": "Bulgaria", "geoPoint": {"lat": 42.68583, "lon": 26.32917}}, {"facility": "Medical Centre Synexus", "city": "Sofia", "zip": "1784", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"facility": "Bispebjerg Og Frederiksberg Hospital", "city": "Copenhagen", "zip": "2400", "country": "Denmark", "geoPoint": {"lat": 55.67594, "lon": 12.56553}}, {"facility": "CHU de Grenoble - Hopital Albert Michallon", "city": "Grenoble Cedex 9", "country": "France", "geoPoint": {"lat": 45.16667, "lon": 5.71667}}, {"facility": "Hopital de Bicetre", "city": "Le Kremlin Bicetre", "zip": "94270", "country": "France", "geoPoint": {"lat": 48.81471, "lon": 2.36073}}, {"facility": "CHU Rouen - Hopital Charles Nicolle", "city": "Rouen Cedex", "zip": "76031", "country": "France", "geoPoint": {"lat": 49.44313, "lon": 1.09932}}, {"facility": "Universit\u00e4tsklinikum Carl Gustav Carus Medizinische Klinik und Poliklinik 1-Pneumologie", "city": "Dresden", "zip": "01307", "country": "Germany", "geoPoint": {"lat": 51.05089, "lon": 13.73832}}, {"facility": "Universitaetsklinikum Giessen", "city": "Giessen", "zip": "35392", "country": "Germany", "geoPoint": {"lat": 50.58727, "lon": 8.67554}}, {"facility": "Universitaetsklinikum Schleswig-Holstein Campus Kiel", "city": "Kiel", "zip": "24105", "country": "Germany", "geoPoint": {"lat": 54.32133, "lon": 10.13489}}, {"facility": "Semmelweis Egyetem V\u00e1rosmajor Sz\u00edv- \u00e9s \u00c9rgy\u00f3gy\u00e1szati Klinika", "city": "Budapest", "zip": "1122", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Barzilai Medical Center", "city": "Ashkelon", "country": "Israel", "geoPoint": {"lat": 31.66926, "lon": 34.57149}}, {"facility": "Hillel Yaffe Medical Center", "city": "Hadera", "zip": "3810101", "country": "Israel", "geoPoint": {"lat": 32.44192, "lon": 34.9039}}, {"facility": "Bnai Zion Medical Center", "city": "Haifa", "zip": "3339419", "country": "Israel", "geoPoint": {"lat": 32.81841, "lon": 34.9885}}, {"facility": "Galilee Medical Center", "city": "Nahariya", "zip": "2210001", "country": "Israel", "geoPoint": {"lat": 33.00892, "lon": 35.09814}}, {"facility": "Rabin Medical Center, Beilinson Campus", "city": "Petah Tikva", "zip": "4941492", "country": "Israel", "geoPoint": {"lat": 32.08707, "lon": 34.88747}}, {"facility": "Kaplan Medical Center", "city": "Rehovot", "zip": "7610001", "country": "Israel", "geoPoint": {"lat": 31.89421, "lon": 34.81199}}, {"facility": "Krakowski Szpital Specjalityczny im. Jana Pawla II, Oddzial Kliniczny Chorob Serca i Naczyn", "city": "Krakow", "zip": "31-202", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "Wojewodzki Szpital Specjalistyczny im. Stefana Kardynala Wyszynskiego SPZOZ", "city": "Lublin", "zip": "20-718", "country": "Poland", "geoPoint": {"lat": 51.25, "lon": 22.56667}}, {"facility": "4 Wojskowy Szpital Kliniczny z Poliklinika SP ZOZ", "city": "Wroclaw", "zip": "50-513", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"facility": "Cardiomed", "city": "Craiova", "zip": "200505", "country": "Romania", "geoPoint": {"lat": 44.31667, "lon": 23.8}}, {"facility": "SAL MED Pitesti", "city": "Pitesti", "zip": "110437", "country": "Romania", "geoPoint": {"lat": 44.85, "lon": 24.86667}}, {"facility": "Cmi Dr Podoleanu Cristian", "city": "Targu-Mures", "zip": "540503", "country": "Romania", "geoPoint": {"lat": 46.54245, "lon": 24.55747}}, {"facility": "Ekaterinburg City Clinical Hospital #14", "city": "Ekaterinburg", "zip": "620039", "country": "Russian Federation", "geoPoint": {"lat": 56.8519, "lon": 60.6122}}, {"facility": "Federal State Budget Scientific Institution", "city": "Kemerovo", "zip": "650002", "country": "Russian Federation", "geoPoint": {"lat": 55.33333, "lon": 86.08333}}, {"facility": "Moscow City Clinical Hospital No.51", "city": "Moscow", "zip": "121309", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Federal State Budgetary Institution", "city": "St Petersburg", "zip": "197341", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Sahlgrenska Universitetsjukhuset", "city": "Goteborg", "zip": "413 45", "country": "Sweden", "geoPoint": {"lat": 57.70716, "lon": 11.96679}}, {"facility": "Royal Free Hospital", "city": "London", "zip": "NW3 2QG", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}, {"facility": "Sheffield Teaching Hospitals NHS Foundation Trust Royal Hallamshire Hospital", "city": "Sheffield", "zip": "S10 2RX", "country": "United Kingdom", "geoPoint": {"lat": 53.38297, "lon": -1.4659}}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \\& Johnson is available at www.janssen.com/clinical-trials\\\\transparency. As noted on this site, requests for access to the study data can be submitted through Yale open Access (YODA) Project site at yoda.yale.edu", "url": "https://www.janssen.com/clinical-trials/transparency"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Macitentan 10 mg", "description": "Eligible participants who remained in the main study (NCT03153111) for at least 24 weeks after randomization, entered this open-label extension study to receive macitentan 10 milligrams (mg) tablet orally once daily until the end of the treatment (treatment exposure ranged from 0.4 to 126 weeks)."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "91"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "76"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "15"}]}], "dropWithdraws": [{"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "11"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Macitentan 10 mg", "description": "Eligible participants who remained in the main study (NCT03153111) for at least 24 weeks after randomization, entered this open-label extension study to receive macitentan 10 milligrams (mg) tablet orally once daily until the end of the treatment (treatment exposure ranged from 0.4 to 126 weeks)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "91"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "72.7", "spread": "9.21"}]}]}]}, {"title": "Age, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "From 18 to 64 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "14"}]}]}, {"title": "From 65 to 84 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "69"}]}]}, {"title": "85 years and over", "categories": [{"measurements": [{"groupId": "BG000", "value": "8"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "59"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "32"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "4"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "86"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "1"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "American Indian or Alaska Native", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}]}]}, {"title": "Black or African American", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}]}]}, {"title": "Native Hawaiian or Other Pacific Islander", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}]}]}, {"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "87"}]}]}, {"title": "More than one race", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}]}]}, {"title": "Unknown or Not Reported", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}]}]}]}, {"title": "Region of Enrollment", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "ARGENTINA", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}]}]}, {"title": "AUSTRIA", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}]}]}, {"title": "BRAZIL", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}]}]}, {"title": "BULGARIA", "categories": [{"measurements": [{"groupId": "BG000", "value": "8"}]}]}, {"title": "DENMARK", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}]}]}, {"title": "FRANCE", "categories": [{"measurements": [{"groupId": "BG000", "value": "5"}]}]}, {"title": "GERMANY", "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}]}]}, {"title": "ISRAEL", "categories": [{"measurements": [{"groupId": "BG000", "value": "23"}]}]}, {"title": "POLAND", "categories": [{"measurements": [{"groupId": "BG000", "value": "7"}]}]}, {"title": "ROMANIA", "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}]}]}, {"title": "RUSSIAN FEDERATION", "categories": [{"measurements": [{"groupId": "BG000", "value": "14"}]}]}, {"title": "SWEDEN", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}]}]}, {"title": "UNITED KINGDOM", "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}]}]}, {"title": "UNITED STATES", "categories": [{"measurements": [{"groupId": "BG000", "value": "14"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Participants With All-cause Deaths up to 30 Days After Study Treatment Discontinuation", "description": "Number of participants with all-cause deaths up to 30 days after study treatment discontinuation were reported. All-cause deaths are defined as all anticipated and unanticipated deaths due to any cause.", "populationDescription": "The safety analysis set included all participants who received at least 1 dose of macitentan 10 milligrams (mg).", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to 30 days after study treatment discontinuation (treatment exposure ranged from 0.4 to 126 weeks)", "groups": [{"id": "OG000", "title": "Macitentan 10 mg", "description": "Eligible participants who remained in the main study (NCT03153111) for at least 24 weeks after randomization, entered this open-label extension study to receive macitentan 10 milligrams (mg) tablet orally once daily until the end of the treatment (treatment exposure ranged from 0.4 to 126 weeks)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "91"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "11"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants With All-cause Hospital Admissions up to 30 Days After Study Treatment Discontinuation", "description": "Number of participants with all-cause hospital admissions up to 30 days after study treatment discontinuation were reported.", "populationDescription": "The safety analysis set included all participants who received at least 1 dose of macitentan 10 mg.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to 30 days after study treatment discontinuation (treatment exposure ranged from 0.4 to 126 weeks)", "groups": [{"id": "OG000", "title": "Macitentan 10 mg", "description": "Eligible participants who remained in the main study (NCT03153111) for at least 24 weeks after randomization, entered this open-label extension study to receive macitentan 10 milligrams (mg) tablet orally once daily until the end of the treatment (treatment exposure ranged from 0.4 to 126 weeks)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "91"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "42"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) up to 30 Days After Study Treatment Discontinuation", "description": "An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is a suspected transmission of any infectious agent via a medicinal product, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above. Any AE and SAE occurring at or after the study treatment start up to 30 days after end of treatment (EOT) within the analysis set was considered to be treatment-emergent.", "populationDescription": "The safety analysis set included all participants who received at least 1 dose of macitentan 10 mg.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to 30 days after study treatment discontinuation (treatment exposure ranged from 0.4 to 126 weeks)", "groups": [{"id": "OG000", "title": "Macitentan 10 mg", "description": "Eligible participants who remained in the main study (NCT03153111) for at least 24 weeks after randomization, entered this open-label extension study to receive macitentan 10 milligrams (mg) tablet orally once daily until the end of the treatment (treatment exposure ranged from 0.4 to 126 weeks)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "91"}]}], "classes": [{"title": "TEAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "81"}]}]}, {"title": "TESAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "49"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants With TEAEs Leading to Premature Discontinuation of Study Treatment", "description": "An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. Any AE occurring at or after the study treatment start up to 30 days after EOT within the analysis set was considered to be treatment-emergent.", "populationDescription": "The safety analysis set included all participants who received at least 1 dose of macitentan 10 mg.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to 30 days after study treatment discontinuation (treatment exposure ranged from 0.4 to 126 weeks)", "groups": [{"id": "OG000", "title": "Macitentan 10 mg", "description": "Eligible participants who remained in the main study (NCT03153111) for at least 24 weeks after randomization, entered this open-label extension study to receive macitentan 10 milligrams (mg) tablet orally once daily until the end of the treatment (treatment exposure ranged from 0.4 to 126 weeks)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "91"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "25"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Systolic and Diastolic Arterial Blood Pressure (BP) at Week 24", "description": "Change from baseline in systolic and diastolic arterial BP at Week 24 was reported.", "populationDescription": "The safety analysis set included all participants who received at least 1 dose of macitentan 10 mg. Here, \"N\" (number of participants analyzed) specifies number of participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "millimeters of mercury (mmHg)", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Macitentan 10 mg", "description": "Eligible participants who remained in the main study (NCT03153111) for at least 24 weeks after randomization, entered this open-label extension study to receive macitentan 10 milligrams (mg) tablet orally once daily until the end of the treatment (treatment exposure ranged from 0.4 to 126 weeks)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "62"}]}], "classes": [{"title": "Systolic BP", "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.01", "spread": "13.152"}]}]}, {"title": "Diastolic BP", "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.34", "spread": "9.903"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Systolic and Diastolic Arterial Blood Pressure (BP) at Week 52", "description": "Change from baseline in systolic and diastolic arterial BP at Week 52 was reported.", "populationDescription": "The safety analysis set included all participants who received at least 1 dose of macitentan 10 mg. Here, \"N\" (number of participants analyzed) specifies number of participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 52", "groups": [{"id": "OG000", "title": "Macitentan 10 mg", "description": "Eligible participants who remained in the main study (NCT03153111) for at least 24 weeks after randomization, entered this open-label extension study to receive macitentan 10 milligrams (mg) tablet orally once daily until the end of the treatment (treatment exposure ranged from 0.4 to 126 weeks)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "53"}]}], "classes": [{"title": "Systolic BP", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.10", "spread": "20.855"}]}]}, {"title": "Diastolic BP", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.79", "spread": "11.685"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Pulse Rate at Week 24", "description": "Change from baseline in pulse rate at Week 24 was reported.", "populationDescription": "The safety analysis set included all participants who received at least 1 dose of macitentan 10 mg. Here, \"N\" (number of participants analyzed) specifies number of participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "beats per minute (bpm)", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Macitentan 10 mg", "description": "Eligible participants who remained in the main study (NCT03153111) for at least 24 weeks after randomization, entered this open-label extension study to receive macitentan 10 milligrams (mg) tablet orally once daily until the end of the treatment (treatment exposure ranged from 0.4 to 126 weeks)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "62"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.59", "spread": "9.706"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Pulse Rate at Week 52", "description": "Change from baseline in pulse rate at Week 52 was reported.", "populationDescription": "The safety analysis set included all participants who received at least 1 dose of macitentan 10 mg. Here, \"N\" (number of participants analyzed) specifies number of participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "bpm", "timeFrame": "Baseline and Week 52", "groups": [{"id": "OG000", "title": "Macitentan 10 mg", "description": "Eligible participants who remained in the main study (NCT03153111) for at least 24 weeks after randomization, entered this open-label extension study to receive macitentan 10 milligrams (mg) tablet orally once daily until the end of the treatment (treatment exposure ranged from 0.4 to 126 weeks)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "53"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.62", "spread": "18.441"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Body Weight at Week 24", "description": "Change from baseline in body weight at Week 24 was reported.", "populationDescription": "The safety analysis set included all participants who received at least 1 dose of macitentan 10 mg. Here, \"N\" (number of participants analyzed) specifies number of participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "kilograms (kg)", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Macitentan 10 mg", "description": "Eligible participants who remained in the main study (NCT03153111) for at least 24 weeks after randomization, entered this open-label extension study to receive macitentan 10 milligrams (mg) tablet orally once daily until the end of the treatment (treatment exposure ranged from 0.4 to 126 weeks)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "64"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.25", "spread": "6.353"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Body Weight at Week 52", "description": "Change from baseline in body weight at Week 52 was reported.", "populationDescription": "The safety analysis set included all participants who received at least 1 dose of macitentan 10 mg. Here, \"N\" (number of participants analyzed) specifies number of participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "kg", "timeFrame": "Baseline and Week 52", "groups": [{"id": "OG000", "title": "Macitentan 10 mg", "description": "Eligible participants who remained in the main study (NCT03153111) for at least 24 weeks after randomization, entered this open-label extension study to receive macitentan 10 milligrams (mg) tablet orally once daily until the end of the treatment (treatment exposure ranged from 0.4 to 126 weeks)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "56"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.16", "spread": "8.200"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants With Treatment-emergent Marked Laboratory Abnormalities (MLAs) up to 30 Days After Study Treatment Discontinuation", "description": "Number of participants with treatment-emergent MLAs (Hemoglobin \\[grams/Liter{L}\\], Hematocrit \\[L/L\\], Leukocytes \\[10\\^9cells/L\\], Lymphocytes \\[10\\^9cells/L\\], Alanine Aminotransferase \\[Units/L {U/L}\\], Aspartate Aminotransferase \\[U/L\\], Bilirubin \\[micromoles/L {mcmol/L}\\], Alkaline Phosphatase \\[U/L\\], Creatinine \\[mcmol/L\\], Urea Nitrogen \\[mmol/L\\], Urate \\[mcmol/L\\], Potassium \\[mmol/L\\], Sodium \\[mmol/L\\], Magnesium \\[mmol/L\\], Calcium \\[mmol/L\\] were reported. Abnormalities that occurred after study treatment start and up to 30 days after study treatment discontinuation, that were not present at baseline, were treatment-emergent. Here, \\> signifies greater than; \\< signifies less than; ULN signifies upper limit of normal; and L=Low, H=High, LL=low/low, HH=high/high, LLL=lower/worse than LL, HHH=higher/worse than HH.", "populationDescription": "The safety analysis set included all participants who received at least 1 dose of macitentan 10 mg. Here, \"N\" (number of participants analyzed) specifies number of participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to 30 days after study treatment discontinuation (treatment exposure ranged from 0.4 to 126 weeks)", "groups": [{"id": "OG000", "title": "Macitentan 10 mg", "description": "Eligible participants who remained in the main study (NCT03153111) for at least 24 weeks after randomization, entered this open-label extension study to receive macitentan 10 milligrams (mg) tablet orally once daily until the end of the treatment (treatment exposure ranged from 0.4 to 126 weeks)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "85"}]}], "classes": [{"title": "Hemoglobin:LL<100", "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}]}]}, {"title": "Hematocrit: LL(<0.28-females;<0.32-males)", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}]}]}, {"title": "Leukocytes: HH (>20.0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Lymphocytes: LLL (<0.5)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Lymphocytes: LL (<0.8)", "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}]}]}, {"title": "Alanine Aminotransferase: HH (>3 ULN)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Aspartate Aminotransferase: HH (>3 ULN)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Alkaline Phosphatase: HH (>2.5 ULN)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Bilirubin: HH (>2 ULN)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Bilirubin: HHH (>5 ULN)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Creatinine: HH (>1.5 ULN)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}]}]}, {"title": "Urea Nitrogen: HH (>2.5 ULN)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}]}]}, {"title": "Urate: HH (>590)", "categories": [{"measurements": [{"groupId": "OG000", "value": "15"}]}]}, {"title": "Urate: HHH (>720)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}]}]}, {"title": "Sodium: LLL (<130)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}]}]}, {"title": "Potassium: LLL (<3.0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Potassium: LL (<3.2)", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}]}]}, {"title": "Potassium: HH (>5.5)", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}]}]}, {"title": "Magnesium: HHH (>1.23)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Calcium: LLL (<1.75)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Calcium: LL (<2.0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Hemoglobin at Week 24", "description": "Change from baseline in hemoglobin at Week 24 was reported.", "populationDescription": "The safety analysis set included all participants who received at least 1 dose of macitentan 10 mg. Here, \"N\" (number of participants analyzed) specifies number of participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "grams per liter (g/L)", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Macitentan 10 mg", "description": "Eligible participants who remained in the main study (NCT03153111) for at least 24 weeks after randomization, entered this open-label extension study to receive macitentan 10 milligrams (mg) tablet orally once daily until the end of the treatment (treatment exposure ranged from 0.4 to 126 weeks)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-4.13", "spread": "11.324"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Hemoglobin at Week 52", "description": "Change from baseline in hemoglobin at Week 52 was reported.", "populationDescription": "The safety analysis set included all participants who received at least 1 dose of macitentan 10 mg. Here, \"N\" (number of participants analyzed) specifies number of participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "grams per litre (g/L)", "timeFrame": "Baseline and Week 52", "groups": [{"id": "OG000", "title": "Macitentan 10 mg", "description": "Eligible participants who remained in the main study (NCT03153111) for at least 24 weeks after randomization, entered this open-label extension study to receive macitentan 10 milligrams (mg) tablet orally once daily until the end of the treatment (treatment exposure ranged from 0.4 to 126 weeks)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.10", "spread": "13.241"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Leukocytes and Platelets at Week 24", "description": "Change from baseline in leukocytes and platelets at Week 24 was reported.", "populationDescription": "The safety analysis set included all participants who received at least 1 dose of macitentan 10 mg. Here, \"N\" (number of participants analyzed) specifies number of participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "10^9 cells/L", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Macitentan 10 mg", "description": "Eligible participants who remained in the main study (NCT03153111) for at least 24 weeks after randomization, entered this open-label extension study to receive macitentan 10 milligrams (mg) tablet orally once daily until the end of the treatment (treatment exposure ranged from 0.4 to 126 weeks)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}]}], "classes": [{"title": "Leukocytes", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.078", "spread": "1.6871"}]}]}, {"title": "Platelets", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.39", "spread": "36.102"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Leukocytes and Platelets at Week 52", "description": "Change from baseline in leukocytes and platelets at Week 52 was reported.", "populationDescription": "The safety analysis set included all participants who received at least 1 dose of macitentan 10 mg. Here, \"N\" (number of participants analyzed) specifies number of participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "10^9 cells/L", "timeFrame": "Baseline and Week 52", "groups": [{"id": "OG000", "title": "Macitentan 10 mg", "description": "Eligible participants who remained in the main study (NCT03153111) for at least 24 weeks after randomization, entered this open-label extension study to receive macitentan 10 milligrams (mg) tablet orally once daily until the end of the treatment (treatment exposure ranged from 0.4 to 126 weeks)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}]}], "classes": [{"title": "Leukocytes", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.503", "spread": "1.5090"}]}]}, {"title": "Platelets", "categories": [{"measurements": [{"groupId": "OG000", "value": "-9.02", "spread": "37.285"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Alanine Aminotransferase and Aspartate Aminotransferase at Week 24", "description": "Change from baseline in alanine aminotransferase and aspartate aminotransferase at Week 24 was reported.", "populationDescription": "The safety analysis set included all participants who received at least 1 dose of macitentan 10 mg. Here, \"N\" (number of participants analyzed) specifies number of participants evaluable for this outcome measure; \"n\" specifies those participants who were analyzed for specific category.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units per liter (U/L)", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Macitentan 10 mg", "description": "Eligible participants who remained in the main study (NCT03153111) for at least 24 weeks after randomization, entered this open-label extension study to receive macitentan 10 milligrams (mg) tablet orally once daily until the end of the treatment (treatment exposure ranged from 0.4 to 126 weeks)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}]}], "classes": [{"title": "Alanine Aminotransferase", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.49", "spread": "7.590"}]}]}, {"title": "Aspartate Aminotransferase", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.2", "spread": "7.76"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Alanine Aminotransferase and Aspartate Aminotransferase at Week 52", "description": "Change from baseline in alanine aminotransferase and aspartate aminotransferase at Week 52 was reported.", "populationDescription": "The safety analysis set included all participants who received at least 1 dose of macitentan 10 mg. Here, \"N\" (number of participants analyzed) specifies number of participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "U/L", "timeFrame": "Baseline and Week 52", "groups": [{"id": "OG000", "title": "Macitentan 10 mg", "description": "Eligible participants who remained in the main study (NCT03153111) for at least 24 weeks after randomization, entered this open-label extension study to receive macitentan 10 milligrams (mg) tablet orally once daily until the end of the treatment (treatment exposure ranged from 0.4 to 126 weeks)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}]}], "classes": [{"title": "Alanine Aminotransferase", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.10", "spread": "7.529"}]}]}, {"title": "Aspartate Aminotransferase", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.2", "spread": "6.52"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Bilirubin at Week 24", "description": "Change from baseline in bilirubin at Week 24 was reported.", "populationDescription": "The safety analysis set included all participants who received at least 1 dose of macitentan 10 mg. Here, \"N\" (number of participants analyzed) specifies number of participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "micromoles per liter (mcmol/L)", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Macitentan 10 mg", "description": "Eligible participants who remained in the main study (NCT03153111) for at least 24 weeks after randomization, entered this open-label extension study to receive macitentan 10 milligrams (mg) tablet orally once daily until the end of the treatment (treatment exposure ranged from 0.4 to 126 weeks)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.0970", "spread": "4.20548"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Bilirubin at Week 52", "description": "Change from baseline in bilirubin at Week 52 was reported.", "populationDescription": "The safety analysis set included all participants who received at least 1 dose of macitentan 10 mg. Here, \"N\" (number of participants analyzed) specifies number of participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mcmol/L", "timeFrame": "Baseline and Week 52", "groups": [{"id": "OG000", "title": "Macitentan 10 mg", "description": "Eligible participants who remained in the main study (NCT03153111) for at least 24 weeks after randomization, entered this open-label extension study to receive macitentan 10 milligrams (mg) tablet orally once daily until the end of the treatment (treatment exposure ranged from 0.4 to 126 weeks)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.2041", "spread": "4.65018"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 24", "description": "Change from baseline in eGFR rate at Week 24 was reported.", "populationDescription": "The safety analysis set included all participants who received at least 1 dose of macitentan 10 mg. Here, \"N\" (number of participants analyzed) specifies number of participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "milliliters/minute/1.73 meter square", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Macitentan 10 mg", "description": "Eligible participants who remained in the main study (NCT03153111) for at least 24 weeks after randomization, entered this open-label extension study to receive macitentan 10 milligrams (mg) tablet orally once daily until the end of the treatment (treatment exposure ranged from 0.4 to 126 weeks)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-4.05", "spread": "11.766"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 52", "description": "Change from baseline in eGFR rate at Week 52 was reported.", "populationDescription": "The safety analysis set included all participants who received at least 1 dose of macitentan 10 mg. Here, \"N\" (number of participants analyzed) specifies number of participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "milliliters/minute/1.73 meter square", "timeFrame": "Baseline and Week 52", "groups": [{"id": "OG000", "title": "Macitentan 10 mg", "description": "Eligible participants who remained in the main study (NCT03153111) for at least 24 weeks after randomization, entered this open-label extension study to receive macitentan 10 milligrams (mg) tablet orally once daily until the end of the treatment (treatment exposure ranged from 0.4 to 126 weeks)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.80", "spread": "13.510"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Up to 30 days after study treatment discontinuation (treatment exposure ranged from 0.4 to 126 weeks)", "description": "The safety analysis set included all participants who received at least 1 dose of macitentan 10 milligrams (mg).", "eventGroups": [{"id": "EG000", "title": "Macitentan 10 mg", "description": "Eligible participants who remained in the main study (NCT03153111) for at least 24 weeks after randomization, entered this open-label extension study to receive macitentan 10 milligrams (mg) tablet orally once daily until the end of the treatment (treatment exposure ranged from 0.4 to 126 weeks).", "deathsNumAffected": 11, "deathsNumAtRisk": 91, "seriousNumAffected": 49, "seriousNumAtRisk": 91, "otherNumAffected": 45, "otherNumAtRisk": 91}], "seriousEvents": [{"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 91}]}, {"term": "Acute Left Ventricular Failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Angina Pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Atrial Fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 91}]}, {"term": "Atrioventricular Block Complete", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Bradycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Cardiac Arrest", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Cardiac Failure Acute", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Cardiac Failure Chronic", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Cardiac Failure Congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 91}]}, {"term": "Left Ventricular Failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 91}]}, {"term": "Right Ventricular Failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 91}]}, {"term": "Sinus Node Dysfunction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Retinal Vein Thrombosis", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Abdominal Incarcerated Hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Ascites", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Duodenal Ulcer Haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Gastrointestinal Haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 91}]}, {"term": "Ileus", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Chest Pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "No Adverse Event", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Non-Cardiac Chest Pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Ulcer Haemorrhage", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Cholecystitis Acute", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 91}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Covid-19", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Covid-19 Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 91}]}, {"term": "Herpes Zoster", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 91}]}, {"term": "Pneumonia Viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 91}]}, {"term": "Limb Injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Subcutaneous Haematoma", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Wound Dehiscence", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Blood Potassium Increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "International Normalised Ratio Increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Sars-Cov-2 Test Positive", "organSystem": "Investigations", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Fluid Retention", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Hyperglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Hyperkalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Intervertebral Disc Protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Colon Cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Malignant Neoplasm of Unknown Primary Site", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Metastases to Peritoneum", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Plasma Cell Myeloma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Small Intestine Carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Uterine Neoplasm", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Cerebrovascular Accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 91}]}, {"term": "Ischaemic Stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Radiculopathy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Acute Kidney Injury", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 91}]}, {"term": "Renal Impairment", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 91}]}, {"term": "Urinary Retention", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Acute Respiratory Failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Dyspnoea Exertional", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Haemoptysis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Pleural Effusion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Pulmonary Embolism", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Pulmonary Hypertension", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Cardiac Pacemaker Replacement", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Cholecystectomy", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Small Intestinal Resection", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Thyroidectomy", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}]}], "otherEvents": [{"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 91}]}, {"term": "Right Ventricular Failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 91}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 91}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 91}]}, {"term": "Oedema Peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 91}]}, {"term": "Upper Respiratory Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 91}]}, {"term": "Urinary Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 91}]}, {"term": "Haemoglobin Decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 91}]}, {"term": "Weight Increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 91}]}, {"term": "Back Pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 91}]}, {"term": "Pain in Extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 91}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 91}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 91}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA Version 24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 91}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Limited number of efficacy parameters were assessed in an exploratory manner. Study was stopped prematurely as main double-blind study did not meet the primary efficacy outcome measure."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 30 days before submission for publication or presentation."}, "pointOfContact": {"title": "Clinical Scientific Leader", "organization": "Actelion Pharmaceuticals Ltd", "email": "ClinicalTrialDisclosure@its.jnj.com", "phone": "844-434-4210"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2020-11-26", "uploadDate": "2022-10-12T10:51", "filename": "Prot_000.pdf", "size": 1666226}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2021-11-02", "uploadDate": "2022-10-12T10:51", "filename": "SAP_001.pdf", "size": 1615571}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Czechia"]}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}, {"id": "D000014652", "term": "Vascular Diseases"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "asFound": "Vascular Disease", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000533860", "term": "Macitentan"}], "ancestors": [{"id": "D000065130", "term": "Endothelin A Receptor Antagonists"}, {"id": "D000065128", "term": "Endothelin Receptor Antagonists"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000065131", "term": "Endothelin B Receptor Antagonists"}], "browseLeaves": [{"id": "M258148", "name": "Macitentan", "asFound": "Neovascular", "relevance": "HIGH"}, {"id": "M12505", "name": "Nitrazepam", "relevance": "LOW"}, {"id": "M30468", "name": "Endothelin A Receptor Antagonists", "relevance": "LOW"}, {"id": "M30466", "name": "Endothelin Receptor Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AntiConv", "name": "Anticonvulsants"}, {"abbrev": "CNSDep", "name": "Central Nervous System Depressants"}, {"abbrev": "PsychDr", "name": "Psychotropic Drugs"}]}}, "hasResults": true}